Assay Detail
Binding
CHEMBL4383832
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of human DAPK1 (1 to 363 residues) using KKLNRTLSFAEPG as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method
12
Total Activities
12
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 12 | 5.42 | 5.90 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4461911 | — | — | 1 | 5.90 |
| CHEMBL4467582 | — | — | 1 | 5.58 |
| CHEMBL4461940 | — | — | 1 | 5.57 |
| CHEMBL4464585 | — | — | 1 | 5.56 |
| CHEMBL4521651 | — | — | 1 | 5.37 |
| CHEMBL4568513 | — | — | 1 | 5.13 |
| CHEMBL4459764 | — | — | 1 | 4.84 |
| CHEMBL4585766 | — | — | 1 | - |
| CHEMBL4522113 | — | — | 1 | - |
| CHEMBL4434760 | — | — | 1 | - |
| CHEMBL4443393 | — | — | 1 | - |
| CHEMBL4587860 | — | — | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4461911 | — | IC50 | = | 1250.0 | nM | 5.90 |
| CHEMBL4467582 | — | IC50 | = | 2610.0 | nM | 5.58 |
| CHEMBL4461940 | — | IC50 | = | 2690.0 | nM | 5.57 |
| CHEMBL4464585 | — | IC50 | = | 2770.0 | nM | 5.56 |
| CHEMBL4521651 | — | IC50 | = | 4290.0 | nM | 5.37 |
| CHEMBL4568513 | — | IC50 | = | 7440.0 | nM | 5.13 |
| CHEMBL4459764 | — | IC50 | = | 14300.0 | nM | 4.84 |
| CHEMBL4585766 | — | IC50 | - | — | - | |
| CHEMBL4522113 | — | IC50 | - | — | - | |
| CHEMBL4434760 | — | IC50 | - | — | - | |
| CHEMBL4443393 | — | IC50 | - | — | - | |
| CHEMBL4587860 | — | IC50 | - | — | - |